Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) has announced equity awards granted to 39 new employees hired in Q1 2025 under its 2024 Employment Commencement Incentive Plan. The grants, approved by the Compensation Committee and compliant with Nasdaq Listing Rule 5635(c)(4), include:
- 31,344 stock options with an exercise price of $63.82 per share
- 77,442 restricted stock units (RSUs)
The stock options will vest over four years, with 25% vesting after one year and the remaining vesting monthly at 1/48th. RSUs will vest annually at 25% over four years. Both are subject to continued employment.
Sarepta Therapeutics (NASDAQ:SRPT) has launched the 8th Annual Route 79 Duchenne Scholarship Program for the 2025-2026 academic year. The program will award academic scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of those affected.
Applications will be accepted until May 30, 2025, with recipients notified before August 2025. Eligible applicants must be accepted to or enrolled in an accredited U.S. college, university, or trade school. The selection process is conducted by an independent committee, with awards distributed for fall 2025 enrollment.
The scholarship program, named after the 79 exons of the dystrophin gene, allows recipients to receive awards up to four times. Selection is made without consideration of whether applicants use Sarepta products or therapies.
Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q4 2024 financial results with net product revenues of $638.2 million, up 75% year-over-year. ELEVIDYS, their gene therapy for Duchenne muscular dystrophy, generated $384.2 million in quarterly revenue, with additional $4.9 million in royalties from Roche sales.
The company achieved GAAP net income of $159.0 million and non-GAAP net income of $206.0 million in Q4 2024. For 2025, Sarepta projects net product revenue guidance of $2.9-3.1 billion, representing 70% year-over-year growth.
Key developments include establishing a $600 million credit facility, positive EMBARK study results for ELEVIDYS, and a global licensing agreement with Arrowhead Pharmaceuticals for siRNA programs. The company completed enrollment in the EMERGENE Phase 3 trial for LGMD2E/R4 gene therapy, with data expected in H1 2025.
Sarepta Therapeutics (NASDAQ:SRPT) has secured a $600 million senior secured revolving credit facility through a bank syndicate led by JPMorgan Chase Bank. This non-dilutive financing arrangement enhances the company's financial flexibility while complementing its existing strong balance sheet.
The credit facility, which received oversubscribed demand, demonstrates lenders' confidence in Sarepta's future cash and EBITDA growth trajectory. The syndicate includes major financial institutions such as Barclays Bank, Citizens Bank, Goldman Sachs USA, Morgan Stanley, Royal Bank of Canada, Fifth Third Bank, UBS AG, and Bank of America.
The facility is designed to provide contingent liquidity as the company executes its strategic plan toward achieving its Sarepta 2030 objectives.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced it will release its fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, February 26, 2025.
The company will host a conference call at 4:30 p.m. E.T. to discuss the results. The event will be webcast live on Sarepta's investor relations website, with a replay available for one year. Phone participants must register online to receive dial-in details and a personal PIN for access.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). The deal includes a $500 million upfront payment and $325 million through Sarepta's purchase of Arrowhead stock at $27.25 per share. Additionally, Arrowhead will receive $250 million in annual $50 million installments over 5 years.
The agreement covers multiple clinical-stage programs including ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-DM1 for myotonic dystrophy, ARO-MMP7 for idiopathic pulmonary fibrosis, and ARO-ATXN2 for spinocerebellar ataxia 2. Three preclinical programs are also included. Arrowhead can earn up to $300 million in near-term payments for ARO-DM1 study enrollment, plus development milestones of $110-410 million and sales milestones of $500-700 million per program, along with tiered royalties up to low double digits.
Sarepta Therapeutics (SRPT) announced positive topline results from Part 2 of the EMBARK study for ELEVIDYS, their approved gene therapy for Duchenne muscular dystrophy. Crossover-treated patients showed significant improvements, with a 2.34-point increase in North Star Ambulatory Assessment (NSAA) compared to controls (P0.0001).Two-year results demonstrated sustained benefits, with Part 1 patients showing clinically meaningful improvements in NSAA (+2.88 points), Time to Rise, and 10-meter walk/run tests compared to external controls. Muscle biopsies at 64 weeks showed consistent expression of ELEVIDYS micro-dystrophin, supporting the observed functional outcomes.
MRI results revealed minimal muscle pathology progression, and no new safety signals were observed. The therapy is currently approved in the U.S. and several other countries for patients aged four years and over.
Sarepta Therapeutics (SRPT) reported strong preliminary Q4 and full-year 2024 financial results, with total net product revenue reaching $638.2 million for Q4 and $1.79 billion for full-year 2024, exceeding guidance by over $100 million. ELEVIDYS, their gene therapy treatment, generated $384.2 million in Q4 revenue and $820.8 million for the full year, surpassing expectations by over $60 million.
The company's RNA-based PMO products contributed $254.0 million in Q4 and $967.2 million for the full year. Year-end cash position stood at approximately $1.5 billion. Sarepta maintains its 2025 revenue guidance of $2.9 to $3.1 billion. Total net product revenue grew 75% year-over-year in Q4, with ELEVIDYS showing 112% growth over the previous quarter.
Hansa Biopharma has announced its attendance at the 43rd Annual J.P. Morgan Healthcare Conference, following significant achievements across three therapeutic areas in the past 12 months. In Autoimmune, the company reported positive data from the Phase 2 trial in Guillain Barre Syndrome and completed enrollment for the Phase 3 anti-GBM trial. Their second-generation IgG cleaving molecule, HNSA-5487, showed promising 12-month analysis results.
In Gene Therapy, Hansa initiated two significant trials: a Phase 1b trial in Duchenne Muscular Dystrophy with Sarepta Therapeutics and a Phase 2 trial in Crigler-Najjar Syndrome with Genethon. The Transplantation segment saw completion of ConfIdeS trial randomization and record-breaking IDEFIRIX quarterly sales of 69.5 MSEK in Q3 2024.
Key 2025 milestones include data readouts from multiple trials and a planned BLA submission to the FDA in the second half of the year. The company continues to develop novel immunomodulating therapies based on its proprietary IgG cleaving platform.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's senior management will deliver a presentation on Monday, January 13, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.
The presentation will be followed by a Q&A session starting at 12:20 p.m. ET / 9:20 a.m. PT. Investors and interested parties can access the live webcast through the Events & Presentations section of Sarepta's investor relations website. The presentation recording will remain available on the website for 90 days afterward. Attendees are advised to connect early to allow time for any necessary software downloads.